17 / 19
Page 69
Notes:
conferenceseries
.com
Volume 6
Journal of Neurological Disorders
ISSN: 2329-6895
CNS 2018
November 12-13, 2018
November 12-13, 2018 | Edinburgh, Scotland
4
th
International Conference on
Central Nervous System Disorders & Therapeutics
CNS clinical trials-the challenges
Susan McGoldrick
The CNS Company, Stirling, Scotland, UK
T
he failure rate for drugs in late-stage clinical trials is high; however, in CNS disorders it is spectacularly high. For example,
in Alzheimer’s disease, 99.6% of drugs in phase III clinical trials have failed. Since the burden of CNS disease is extremely
high, the demand for treatments exists and is ever growing. From all the trial failures, there are, therefore, a huge amount of
lessons that can be learnt if you are willing to look honestly at what has gone wrong and consider taking a different path. This
talk will look at the lessons that can be learned from poor patient selection, endpoint selection and poor trial design resulting
in high screen failures and withdrawals.
Susan_McGoldrick@tctcgroup.comJ Neurol Disord 2018, Volume 6
DOI: 10.4172/2329-6895-C9-050